Celebrex CV risk outweighs cancer benefit
Executive Summary
Final analysis of Celebrex colon cancer prevention studies indicates cardiovascular risk "outweighs what may be an optimistic projection of its potential benefit in decreasing colorectal cancer events," editorial by Bruce Psaty and John Potter states. Pfizer's Adenoma Prevention with Celecoxib (APC) and Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trials were published in the New England Journal of Medicine Aug. 31. Celebrex labeling was updated to reflect the CV results of the trials last year (1"The Pink Sheet" Aug. 8, 2005, p. 6). Editorial also charges studies were too small to evaluate celecoxib's role in preventing colorectal cancer. "It is reasonable to conclude that celecoxib has no role as a chemopreventive agent either in patients with nonfamilial colonic adenomas or in the general population," the editorial concludes...
You may also be interested in...
Pfizer Celebrex Revised Labeling Adds Class Cardio Risk, Moves Safety Data
Pfizer appears to have used the relabeling of its COX-2 inhibitor Celebrex to add class cardiovascular risk language as an opportunity to renegotiate the placement of safety data
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.